Navigation Links
Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
Date:8/29/2007

SOUTH SAN FRANCISCO, Calif., Aug. 29 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that it will hold a webcast briefing for analysts and investors in conjunction with the International Association for the Study of Lung Cancer's (IASLC) 12th World Conference on Lung Cancer. The webcast will be held on Wednesday, September 5, 2007, at 5:00 a.m. PDT/8:00 a.m. EDT. During the webcast, Exelixis management will discuss data from a Phase 2 trial of XL647 in non-small cell lung cancer patients presented at the Conference.

The webcast may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

An archive of this webcast will be available until 8:59 p.m. PDT/11:59 p.m. EDT on October 5, 2007. Access numbers for this replay are 888-286-8010 (domestic) and 617-801-6888 (international). The replay passcode is 18807116.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site a
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015  BiOptix is pleased to announce the appointment ... of Chemistry and Biochemistry. Scott joins the company after previous ... Amgen throughout the course of his nearly 20 year ... is a nationally recognized thought leader in the biosensor ...
(Date:1/22/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced that it ... on Tuesday, Jan. 27, 2015, after the close of the U.S. ... with the investment community at 2 p.m. PT. Participating in the ... and chief executive officer, and other members of Amgen,s senior management ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) has announced ... by Product, Application, Technology, End User - Global Forecast ... The infectious disease diagnostics market is expected to ... by 2019 from $12,422.8 million in 2014. Increase in ...
Breaking Medicine Technology:BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... , , , , ... , THE WOODLANDS, Texas, July 21 ... biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, ... for Orphan Medical Products (COMP) of the European Medicines Agency (EMEA) for ...
... , TOKYO, July 21 R-Tech Ueno, Ltd. ... on the new compound RK-023 that is being developed by our ... see the note below) has been completed. , ... of a patch test (open, closed, photo-patch test), single-dose study and ...
Cached Medicine Technology:Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA 2Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA 3Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA 4R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023 2R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023 3
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... 20 years, Dr. David Cruz of Cruz Chiropractic Care ... about every type of injury that can result from car accidents ... years, the team at Doctors on Liens has been ... With the combined breadth of experience between the two, ...
(Date:1/22/2015)... has added many trendy Champagne wedding dresses to ... the past three years. Today, the business announces a special ... the sales manager of the company, this is on the ... point can be reflected on the discounted wedding dresses from ...
(Date:1/22/2015)... 22, 2015 As interest in the value ... gains momentum worldwide, Rev. Eric J. Hall , president ... (HCCN), will be the keynote speaker on January 27 ... public health system. , The conference, “Hope and Resilience: Innovative ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... will receive more than $6 million in federal funding ... abuse and associated problems among U.S. military personnel, veterans, ... (NIDA), part of the National Institutes of Health, is ... grants that will examine substance abuse related to deployment ...
... University of Minnesota,s Institute for Mathematics and its Applications ... (NSF) renewal grant over the next five years. The ... the nation,s top math institutes in terms of funding. ... of Minnesota,s College of Science and Engineering, is one ...
... adenovirus to sidestep the cell,s suicide program, could go a ... in tumor cells and pave the way for a new ... Institute for Biological Studies in the Aug. 26, 2010 issue ... stress, the tumor suppressor p53 springs into action activating an ...
... Reporter , WEDNESDAY, Aug. 25 (HealthDay News) -- If you ... can be easily worked off at the gym, think again. ... worth of unhealthy living changes physiology, making piled-on fat even ... have later long-term effects," said study co-author Dr. Torbjorn Lindstrom, ...
... at Mayo Clinic discovered several years ago that laboratory samples ... to help them find new treatments for this lethal disease ... became evident that the situation in their lab was common ... that were supposed to originate from patients with this rare ...
... Gardner HealthDay Reporter , TUESDAY, Aug. 24 ... to Monday,s decision by a U.S. judge to ... funds. The temporary injunction, which basically blindsided the ... to the pre-2001 days. That was when then-President Bush ...
Cached Medicine News:Health News:Studies on combat-related substance use and abuse to be funded by NIH and VA 2Health News:Studies on combat-related substance use and abuse to be funded by NIH and VA 3Health News:University of Minnesota math institute receives $20.5 million NSF grant 2Health News:Use the common cold virus to target and disrupt cancer cells? 2Health News:Use the common cold virus to target and disrupt cancer cells? 3Health News:Short-Term Overeating Could Make Long-Term Weight Loss Tougher 2Health News:Mayo researchers develop new laboratory cell lines to study treatment for ATC 2Health News:Mayo researchers develop new laboratory cell lines to study treatment for ATC 3Health News:Scientists Dismayed by Stem Cell Research Ruling 2Health News:Scientists Dismayed by Stem Cell Research Ruling 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: